key: cord-0912730-bvkt1w3a
authors: Zhao, Xin; Li, Dedong; Ruan, Wenjing; Chen, Zhihai; Zhang, Rong; Zheng, Anqi; Qiao, Shitong; Zheng, Xinlei; Zhao, Yingze; Dai, Lianpan; Han, Pengcheng; Gao, George F.
title: Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant
date: 2022-01-26
journal: N Engl J Med
DOI: 10.1056/nejmc2119426
sha: f591adf5738868cdc433e3215f31a98f22bb5ffd
doc_id: 912730
cord_uid: bvkt1w3a

nan

The construction of VSV-ΔG-GFP based SARS-CoV-2 pseudotyped virus was 

Software provided with CQ1 confocal image cytometer was used to calculate the TU numbers of neutralization assay and the statistical analyses were performed by GraphPad Prism 8.0 (GraphPad Software Inc.). pVNT50 were determined by a nonlinear regression. pVNT50 below the lower limit of detection (<20) was recorded as 10 in the geometric mean calculation. Neutralization between prototype and different variants were compared using a two-tailed Wilcoxon matched-pairs signed rank test.

In this work, we used VSV-based SARS-CoV-2 spike pseudovirus neutralization (pVN) assay to test the NAb titer against SARS-CoV-2 prototype and its variants. The pVN assay were widely used for SARS-CoV-2 drug and vaccine evaluation. Although in most cases, the neutralizing titers tested in the pVN assay are higher than they are in the live-virus assay, there is a high correlation between them 4-7 . However, here are also some limitations in the pVN assay in vaccine evaluation. Furthermore, the T-cell immunity, which was activated mostly by the mRNA and viral-vector vaccine, could also contribute to the real-world protection against Omicron variant 8 . Indeed, as a protein subunit vaccine, ZF2001 could elicit moderate Th1 and Th2 responses as detected in the Phase 1 and 2 trials 9 . Besides, the high transmission ability of Omicron could also weaken the protection provided by vaccines. Considering above, we still need more real-world data to evaluate the vaccine effectiveness.

In this work, we paid attention to the different regimens of ZF2001 vaccination.

We found that a longer interval between the second and third shot would be beneficial to elicit NAbs against Omicron. This is in accordance with our previous work on other VOC and VOIs such as Delta 2 . Moreover, data from the clinical trial of ChAdOx1 nCoV-19 (AZD1222) vaccine showed better vaccine efficacy with a longer booster interval 10 . The booster shot would provide higher NAb titers against Omicron, which has also been found in mRNA vaccine and inactivated vaccines [11] [12] [13] [14] . As

Omicron pushes cases to records, shortening the await time for people to receive their booster vaccination was considered in many countries. Therefore, our work would 5 further raise the public concern that enough vaccination interval would be required to elicit better responses in neutralization of Omicron. The ZF2001 (0, 1, 5) group were sub-divided in to the 0, 1, (4-5) and 0, 1, >5 groups.

GMT with 95% confidence intervals (CIs) is shown. No significant difference were detected between the two groups. The sequences were mammalian-preferred codon-optimized. The different nucleotides were marked in red. *: Here we used the date that the Nuclei acid tests negative twice consecutively and meets the discharge criteria in China. The convalescents samples were collected in July-August, 2020. Vaccinee serum samples were collected in February-December, 2021.

A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS

Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants

Binding and molecular basis of the bat coronavirus RaTG13 virus to ACE-2 in humans and other species

The first Chinese national standards for SARS-CoV-2 neutralizing antibody

Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

SARS-CoV-2 T cell responses are expected to remain robust against Omicron. bioRxiv

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, doubleblind, placebo-controlled, phase 1 and 2 trials

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Broadly neutralizing antibodies overcome SARS-CoV-2

Omicron antigenic shift

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

SARS-CoV-2 Omicron spike mediated immune escape, infectivity and cell-cell fusion. bioRxiv

Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost

We thank Beijing Ditan Hospital and all volunteers. This work was supported by the National Key R&D Program of China (2020YFA0907102 and 2020YFA0509202). 

GFG conceived and designed the study. GFG, XZ, PH, LD and ZC designed, and